Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.72 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | RHOC | P08134 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.64 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.64 |
| ▸ | PDE6D | O43924 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364849 | 0.90 | HMGCR (0.66) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL14414149 | 0.87 | SLCO1B1 (0.80) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL12073345 | 0.86 | HMGCR (0.72) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL14142005 | 0.86 | SLCO1B1 (0.69) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL14142004 | 0.86 | SLCO1B1 (0.69) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL5808035 | 0.86 | SLCO1B1 (0.66) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL5809239 | 0.85 | HMGCR (0.71) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL12192335 | 0.85 | HMGCR (0.77) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL12210219 | 0.85 | SLCO1B1 (0.75) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 | |
| SCHEMBL10018612 | 0.85 | SLCO1B1 (0.75) | HMGCRSLCO1B1ABCB1ABCC2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240442-B1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO LTD (KR) | 2012-06-20 | — | — | EP | disclosed |
| US-8124790-B2 | Preparation process useful in synthesis of atorvastatin | MEDICHEM KOREA CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| WO-2009084773-A2 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA. CO., LTD. (KR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009054693-A2 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-04-30 | — | — | WO | disclosed |
| US-4681893-A | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | HMGCR, DHCR7, LIPA | HMGCR 1/4885SLCO1B1 776/4885ABCB1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.